<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02090959</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-020e-DMD</org_study_id>
    <nct_id>NCT02090959</nct_id>
  </id_info>
  <brief_title>An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy</brief_title>
  <official_title>A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to obtain long term safety data of ataluren in boys
      with nonsense mutation dystrophinopathy (who participated and completed a previous Phase 3
      study of ataluren [PTC124-GD-020-DMD {NCT01826487}]) to augment the overall safety database.
      Screening and baseline procedures are structured to avoid a gap in treatment between the
      double-blind study (PTC124-GD-020-DMD) and this extension study.

      This study may be further extended by amendment until either ataluren becomes commercially
      available or the clinical development of ataluren in duchenne muscular dystrophy (DMD) is
      discontinued.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 31, 2014</start_date>
  <completion_date type="Actual">June 21, 2018</completion_date>
  <primary_completion_date type="Actual">June 21, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events (AEs)</measure>
    <time_frame>Baseline (Day 1) to 6 weeks post-treatment (Week 150)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Abnormalities in Laboratory Parameters</measure>
    <time_frame>Baseline (Day 1) to 6 weeks post-treatment (Week 150)</time_frame>
    <description>Laboratory parameters include hematology and serum biochemistry parameters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Ambulation at Week 144 , as Measured by the 6-Minute Walk Test (6MWT)</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>The 6MWT is an established outcome measure reflecting the global status of all the systems involved in walking, including the neuromuscular, pulmonary, and cardiovascular systems. 6MWT represents an appropriate approach to assessing ambulatory ability in boys with duchenne and becker muscular dystrophy (DBMD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proximal Muscle Function at Week 144, as Assessed by Timed Function Tests (TMTs)</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>TMTs include time to rise from supine position, time to run/walk 10 meters, and time to climb/descend 4 stairs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physical Function at Week 144, as Assessed by the North Star Ambulatory Assessment (NSAA) Score</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>The NSAA consists of 17 activities, each scored as 0, 1, or 2. The sum of these 17 scores will be used to form a total score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Motor Performance of the Upper Limb at Week 144, as Measured by the Performance Upper Limb (PUL) Score</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>The PUL assessment includes 22 items (with an entry item to define starting functional level to avoid testing functional dimensions in which the participant lacks the lower limit of function, and 21 items subdivided into shoulder level (4 items), elbow level (9 items), and distal level (8 items) dimensions. Scoring varies across the scale between 0-1 to 0-6 according to performance. Each dimension will be scored separately with a maximum score of 16 for shoulder level, 34 for elbow level, and 24 for distal level. Total score will be calculated by adding the 3 level scores (maximum global score of 74).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pediatric Outcomes Data Collection Instrument (PODCI) Transfers/Basic Mobility and Sports/Physical Functioning scores at Week 144</measure>
    <time_frame>Baseline, Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Participant and Parent/Caregiver Reported Activities of Daily Living/Disease Status at Week 144</measure>
    <time_frame>Baseline, Week 144</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulmonary Function at Week 144, as Measured by Spirometry</measure>
    <time_frame>Baseline, Week 144</time_frame>
    <description>Pulmonary function test will include forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ataluren Plasma Concentration</measure>
    <time_frame>Pre-dose at Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132 and 144</time_frame>
    <description>Pre-dose ataluren plasma concentrations prior to morning ataluren administration at each clinic visit will be assessed by a validated bioanalytical method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Systolic and Diastolic Blood Pressure at Week 150</measure>
    <time_frame>Baseline, Week 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Pulse Rate at Week 150</measure>
    <time_frame>Baseline, Week 150</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Body Temperature at Week 150</measure>
    <time_frame>Baseline, Week 150</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">219</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <condition>Muscular Dystrophies</condition>
  <condition>Muscular Disorders, Atrophic</condition>
  <condition>Muscular Diseases</condition>
  <condition>Musculoskeletal Diseases</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <arm_group>
    <arm_group_label>Ataluren</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ataluren oral suspension daily 10 milligrams per kilogram (mg/kg) in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for up to 144 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren</intervention_name>
    <description>Ataluren will be administered as per the dose and schedule specified in the arm.</description>
    <arm_group_label>Ataluren</arm_group_label>
    <other_name>PTC124</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Completion of study treatment in the previous Phase 3, double-blind study protocol
             (Protocol PTC124-GD-020-DMD).

          -  Evidence of signed and dated informed consent/assent document(s) indicating that the
             participant (and/or his parent/legal guardian) has been informed of all pertinent
             aspects of the trial. Note: If the study candidate is considered a child under local
             regulation, a parent or legal guardian must provide written consent prior to
             initiation of study screening procedures and the study candidate may be required to
             provide written assent. The rules of the responsible Institutional Review
             Board/Independent Ethic Committee (IRB/IEC) regarding whether one or both parents must
             provide consent and the appropriate ages for obtaining consent and assent from the
             participant should be followed.

          -  In participants who are sexually active, willingness to abstain from sexual
             intercourse or employ a barrier or medical method of contraception during the period
             of study drug administration and 6-week follow-up period.

          -  Willingness and ability to comply with scheduled visits, ataluren administration plan,
             study procedures, laboratory tests, and study restrictions.

        Exclusion Criteria:

          -  Known hypersensitivity to any of the ingredients or excipients of the study drug
             (Litesse® UltraTM [refined polydextrose], polyethylene glycol 3350, Lutrol® micro F127
             [poloxamer 407], mannitol 25C, crospovidone XL10, hydroxyethyl cellulose, vanilla,
             Cab-O-Sil® M5P [colloidal silica], magnesium stearate).

          -  Ongoing participation in any other therapeutic clinical trial.

          -  Prior or ongoing medical condition (for example, concomitant illness, psychiatric
             condition, behavioral disorder, alcoholism, drug abuse), medical history, physical
             findings, electrocardiogram (ECG) findings, or laboratory abnormality that, in the
             investigator's opinion, could adversely affect the safety of the participant, makes it
             unlikely that the course of treatment or follow-up would be completed, or could impair
             the assessment of study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bibbiani, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado - Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Child Neurology Center of Northwest Florida</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Medical Center Dallas, Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital - Childhood Cancer and Blood Disorders</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro - Instituto de Puericultura e Pediatria Martagao Gesteira</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21.941-912</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sao Paulo University -HC/FMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aleksandrovska Hospital</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6C 2RC</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Luis Calvo Mackenna</name>
      <address>
        <city>Santiago</city>
        <state>Región Metropolitana</state>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad Catolica</name>
      <address>
        <city>Santiago</city>
        <zip>8330073</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>635 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Pitie-Salpetriere</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitat Munchen - von Haunersche Kinder Clinic</name>
      <address>
        <city>Munchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Neuropsichiatria Infantile</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario G. Martino</name>
      <address>
        <city>Sicily</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>502-097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Silvia Children's Hospital</name>
      <address>
        <city>Goteburg</city>
        <zip>SE-416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Childrens Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hacettepe Childrens Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erciyes University Faculty of Medicine</name>
      <address>
        <city>Talas/Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University College London Institute of Child Health</name>
      <address>
        <city>London</city>
        <zip>WC1N 3JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals, NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>http://www.ptcbio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2014</study_first_posted>
  <disposition_first_submitted>April 9, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 9, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 12, 2019</disposition_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Dystrophinopathy</keyword>
  <keyword>Nonsense mutation</keyword>
  <keyword>Premature stop codon</keyword>
  <keyword>Becker muscular dystrophy</keyword>
  <keyword>DMD/BMD</keyword>
  <keyword>PTC124</keyword>
  <keyword>Ataluren</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Muscular Disorders, Atrophic</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>July 17, 2020</submitted>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

